Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
12/2003
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103771A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003WO2003103698A1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103664A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103608A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003WO2003103604A2 Gamma lactams as prostaglandin agonists and use thereof
12/18/2003WO2003103590A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003WO2003103583A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003082817A3 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002100293A3 A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002080857A3 Polymorphs of fexofenadine hydrochloride
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003US20030232893 Method of treating rosacea
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232855 Such as N-(benzo(1,3)dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2 -dihydroquinoline-3-carboxamide for stimulation of peripheral cell type cannabinoid receptors
12/18/2003US20030232853 Azabicyclic compounds for the treatment of disease
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232848 Pyrazole compositions
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232845 Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects
12/18/2003US20030232838 6-phenylpyrrolopyrimidinedione derivatives
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232815 Non-peptidic cyclophilin binding compounds and their use
12/18/2003US20030232814 Novel compounds and their use
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232810 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
12/18/2003US20030232802 Aryl and heteroaryl sulfonates
12/18/2003US20030232795 Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity
12/18/2003US20030232791 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003DE10215316C1 Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer Quinoline and isoquinoline derivatives, to a pharmaceutical agent and their use as anti-inflammatory agents
12/18/2003CA2488937A1 Par-2-activating peptide derivative and pharmaceutical composition using the same
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488609A1 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488567A1 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003CA2488497A1 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487977A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003CA2486491A1 4-(aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003CA2485874A1 T cell receptor cdr3 sequences and methods for detection
12/18/2003CA2485709A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003CA2483555A1 Gamma lactams as prostaglandin agonists and use thereof
12/17/2003EP1371650A1 Activator for peroxisome proliferator-activated receptor
12/17/2003EP1371647A2 Pyridine-3-carboxylic acid derivatives and their use as intermediates
12/17/2003EP1371646A1 Aryl-substituted alicyclic compound and medical composition comprising the same
12/17/2003EP1370662A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
12/17/2003EP1370647A2 A dna molecule encoding a variant paraoxonase and uses thereof
12/17/2003EP1370588A2 Human monoclonal antibodies to fc alpha receptor (cd89)
12/17/2003EP1370556A1 Metalloproteinase inhibitors
12/17/2003EP1370553A2 Rho-kinase inhibitors
12/17/2003EP1370552A2 Rho-kinase inhibitors
12/17/2003EP1370542A1 Bicyclic guanidine derivatives and therapeutic uses thereof
12/17/2003EP1370538A1 Metalloproteinase inhibitors
12/17/2003EP1370537A1 Metalloproteinase inhibitors
12/17/2003EP1370536A1 Metalloproteinase inhibitors
12/17/2003EP1370535A1 Metalloproteinase inhibitors
12/17/2003EP1370534A1 Metalloproteinase inhibitors
12/17/2003EP1370533A2 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
12/17/2003EP1370530A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
12/17/2003EP1370521A1 Formanilide derivatives as beta2-adrenoreceptor agonists
12/17/2003EP1370518A2 Tryptase-inhibitors
12/17/2003EP1370513A1 Malic acid addition salts of terbinafine
12/17/2003EP1370297A2 Method and composition
12/17/2003EP1370279A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
12/17/2003EP1370276A2 Medical uses of intercellular communication facilitating compounds
12/17/2003EP1370267A2 Use of propentofylline to control intraocular pressure
12/17/2003EP1370254A2 Copper chelators for treating ocular inflammation
12/17/2003EP1370250A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
12/17/2003EP1370237A2 Presbyopia treatment by lens alteration
12/17/2003EP1370144A1 Noninvasive measurements of chemical substances
12/17/2003EP1272470B1 Amorphous torasemide modification
12/17/2003EP1226131B1 Isoxazolecarboxamide derivatives
12/17/2003EP1162970B1 Anti-inflammatory uses of manzamines
12/17/2003EP1147121B1 Ketolide antibiotics
12/17/2003EP1109799B1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
12/17/2003CN1462276A Peptide-based compounds
12/17/2003CN1462190A The use of copolymer 1 and related peptides and polypeptides and T cell treated therewith for neuroprotective therapy
12/17/2003CN1131241C Cross-linked hyaluronic acids and medical uses thereof
1 ... 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 ... 531